PERTH, Australia – Australian regenerative medicine company Mesoblast Ltd.'s allogeneic cell therapy candidate, MPC-150-IM, failed to meet the primary endpoint in a phase IIb trial in end-stage heart failure patients implanted with a left ventricular assist device (LVAD), but it delivered meaningful clinical results that may make it approvable.

PERTH, Australia – Australia's Cochlear Ltd. said it would fight a U.S. District Court patent infringement verdict reported Monday that doubles the damages Cochlear was ordered to pay the Alfred E. Mann Foundation for Scientific Research and Advanced Bionics LLC. The Federal District Court for the Central District of California awarded "enhanced damages" in the amount of $268 million, and the cochlear implant company will need to lodge a $335 million insurance bond to appeal the judgement.

BRISBANE, Australia – Australia is considered one of the first movers in the regenerative medicine (RM) space, with more than 70 institutes and companies working in the sector across the country. But to capitalize on its technical capabilities, it will need to be strategic if it is to reach its potential to be a major player in Asia Pacific.

PERTH, Australia – Australia’s Therapeutic Goods Administration (TGA) is seeking industry comments on a proposal to introduce a new framework for companion diagnostics.

BRISBANE, Australia – Australia is considered one of the first movers in the regenerative medicine (RM) space, with more than 70 institutes and companies working in the sector across the country. But to capitalize on its technical capabilities, it will need to be strategic if it is to reach its potential to be a major player in Asia Pacific.

PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) is seeking industry comments on a proposal to introduce a new framework for companion diagnostics.